Table 1. Baseline characteristics of patients with biopsy-proven NAFLD stratified by *HSD17B13* rs72613567 genotypes.

| | *HSD17B13* rs72613567 | | | | *HSD17B13* rs72613567 | | |
	-/- group	A/- group	A/A group	*p-value*	-/- group	A/- + A/A group (combined)	*p-value*
N	*n* = 93	*n* = 96	*n* = 26		*n* = 93	*n* = 122	
Clinical parameters							
Male sex, *n* (%)	72 (77.42%)	75 (78.13%)	22 (84.62%)	0.723	72 (77.42%)	97 (79.51%)	0.711
Age, years	40 ± 12	42 ± 14	39 ± 15	0.584	40 ± 12	41 ± 14	0.559
BMI, kg/m^2	27.18 (24.28-29.39)	26.33 (24.62-28.41)	25.96 (23.83-27.84)	0.383	27.18 (24.28-29.39)	26.31 (24.46-28.41)	0.223
WBC, ×10^9/L	6.21 ± 1.37	6.33 ± 1.48	6.02 ± 1.21	0.503	6.21 ± 1.37	6.27 ± 1.43	0.785
RBC, ×10^{12}/L	5.01 ± 0.51	4.96 ± 0.50	5.13 ± 0.53	0.222	5.01 ± 0.51	5.00 ± 0.50	0.878
PLT, ×10^9/L	236.23 ± 62.85	255.70 ± 51.27	240.77 ± 64.19	**0.005**	236.23 ± 62.85	252.52 ± 54.34	**0.043**
ALB, g/L	47.40 ± 3.12	46.53 ± 3.94	47.07 ± 3.69	0.259	47.40 ± 3.12	46.65 ± 3.88	0.128
ALT, U/L	61 (38.00-108.50)	47.50 (31.25-89.50)	68.00 (29.75-115.00)	0.257	61 (38.00-108.50)	51 (31.75-95.00)	0.171
AST, U/L	40 (27.50-64.50)	33.00 (26.00-52.00)	37.50 (25.75-58.75)	0.304	40 (27.50-64.50)	34 (26.00-52.00)	0.148
ALP, U/L	82 (69.50-99.50)	82.50 (67.25-97.75)	84.50 (71.75-109.50)	0.477	82 (69.50-99.50)	82.5 (70.75-101.00)	0.758
GGT, U/L	51 (36.50-83.00)	49.50 (30.50-82.00)	69.00 (36.00-98.50)	0.349	51 (36.50-83.00)	53 (33.75-84.75)	0.908
BUN, mmol/L	4.70 ± 1.39	4.66 ± 1.19	4.95 ± 1.15	0.383	4.70 ± 1.39	4.72 ± 1.19	0.915
SCr, μmol/L	69.11 ± 15.10	66.80 ± 14.21	74.15 ± 17.88	0.166	69.11 ± 15.10	68.37 ± 15.29	0.725
eGFR, ml/min/1.73 m^2	116.72 ± 18.32	119.03 ± 19.01	113.36 ± 25.44	0.402	116.72 ± 18.32	117.82 ± 20.56	0.684
Urinary ACR category				**0.001**			**0.001**
ACR ≥30 mg/g	18 (19.35%)	6 (6.25%)	0		18 (19.35%)	6 (4.92%)	
ACR <30 mg/g	75 (80.65%)	90 (93.75%)	26 (100%)		75 (80.65%)	116 (95.08%)	
Serum UA, μmol/L	411.84 ± 108.63	409.67 ± 116.80	421.15 ± 94.48	0.688	411.84 ± 108.63	412.11 ± 112.15	0.986
Serum NGAL, ng/mL	91.31 (75.57-112.58)	93.16 (71.90-117.47)	87.62 (73.12-105.28)	0.776	91.31 (75.57-112.58)	92.26 (72.04-111.09)	0.790
Urinary NGAL, ng/mL	29.33 (25.12-42.16)	28.61 (24.38-38.42)	30.80 (24.38-39.20)	0.862	29.33 (25.12-42.16)	28.82 (24.43-38.34)	0.604
Triglycerides, mmol/L	1.99 (1.45-2.78)	1.90 (1.37-2.62)	1.84 (1.14-3.19)	0.869	1.99 (1.45-2.78)	1.89 (1.32-2.91)	0.606
Total cholesterol, mmol/L	5.00 ± 1.13	4.87 ± 1.12	4.76 ± 0.91	0.464	5.00 ± 1.13	4.85 ± 1.07	0.302
HDL-cholesterol, mmol/L	0.96 ± 0.19	0.99 ± 0.21	0.97 ± 0.15	0.803	0.96 ± 0.19	0.99 ± 0.20	0.366
LDL-cholesterol, mmol/L	3.09 ± 0.97	3.04 ± 0.97	2.96 ± 0.84	0.741	3.09 ± 0.97	3.02 ± 0.94	0.591
HbA1c, %	5.70 (5.30-6.35)	5.70 (5.40-6.68)	5.65 (5.40-6.73)	0.621	5.70 (5.30-6.35)	5.70 (5.40-6.63)	0.363

HOMA-IR score	3.85 (2.66-5.25)	3.34 (2.16-4.95)	3.80 (2.33-7.99)	0.381	3.85 (2.66-5.25)	3.37 (2.30-5.17)	0.257
Comorbid diseases							
Type 2 diabetes, n (%)	27 (29.03%)	30 (31.25%)	8 (30.77%)	0.945	27 (29.03%)	38 (31.15%)	0.738
Hypertension, n (%)	15 (16.13%)	20 (20.83%)	5 (19.23%)	0.704	15 (16.13%)	25 (20.49%)	0.415
CKD, n (%)	22 (23.66%)	13 (13.54%)	5 (19.23%)	0.198	22 (23.66%)	18 (14.75%)	0.097
Dyslipidemia, n (%)	85 (91.40%)	87 (90.63%)	23 (88.46%)	0.905	85 (91.40%)	110 (90.16%)	0.758
Obesity, n (%)	17 (18.28%)	13 (13.54%)	1 (3.85%)	0.117	17 (18.28%)	14 (11.48%)	0.159
Hyperuricemia, n (%)	45 (48.39%)	47 (48.96%)	15 (57.69%)	0.688	45 (48.39%)	62 (50.82%)	0.724
Liver histology features							
Grading of Steatosis, n (%)				0.126			0.561
1	37 (39.78%)	48 (50.00%)	8 (30.77%)		37 (39.78%)	56 (45.90%)	
2	26 (27.96%)	21 (21.88%)	6 (23.08%)		26 (27.96%)	27 (22.13%)	
3	30 (32.26%)	27 (28.13%)	12 (46.15%)		30 (32.26%)	39 (31.97%)	
Grading of Hepatocyte				0.559			0.306
ballooning, n (%)	3 (3.23%)	4 (4.17%)	1 (3.85%)		3 (3.23%)	5 (4.10%)	
0	47 (50.54%)	55 (57.29%)	14 (53.85%)		47 (50.54%)	69 (56.56%)	
1	43 (46.24%)	37 (38.54%)	11 (42.31%)		43 (46.24%)	48 (39.34%)	
2				0.705			0.672
Grading of Lobular	3 (3.23%)	9 (9.38%)	1 (3.85%)		3 (3.23%)	10 (8.20%)	
inflammation, n (%)	72 (77.42%)	68 (70.83%)	19 (73.08%)		72 (77.42%)	87 (71.31%)	
0	18 (19.35%)	17 (17.71%)	6 (23.08%)		18 (19.35%)	23 (18.85%)	
1	0	2 (2.08%)	0		0	2 (1.64%)	
2				0.546			0.496
3	28 (30.11%)	27 (28.13%)	5 (19.23%)		28 (30.11%)	32 (26.23%)	
Fibrosis stage, n (%)	44 (47.31%)	46 (47.92%)	14 (53.85%)		44 (47.31%)	60 (49.18%)	
0	18 (19.35%)	18 (18.75%)	4 (15.38%)		18 (19.35%)	22 (18.03%)	
1	2 (2.15%)	5 (5.21%)	3 (11.54%)		2 (2.15%)	8 (6.56%)	
2	1 (1.08%)	0	0		1 (1.08%)	0	
3							
4							
NAFLD activity score				0.360			0.447
≥4	67 (72.04%)	62 (64.58%)	20 (76.92%)		67 (72.04%)	82 (67.21%)	
<4	26 (27.96%)	34 (35.42%)	6 (23.07%)		26 (27.96%)	40 (32.79%)	

Sample size, *n*=215. Data are expressed as numbers (percentages) for categorical variables, as means ± SD for normally distributed continuous variables, and as medians (inter-quartile ranges) for not normally distributed continuous variables.

Abbreviations: BMI = body mass index, ALB = albumin, ALT = alanine aminotransferase, AST = aspartate aminotransferase, ALP = alkaline phosphatase, GGT = gamma-glutamyl transferase, BUN = blood urea nitrogen, SCr = serum creatinine, eGFR = estimated glomerular filtration rate, ACR = albumin to creatinine ratio, UA = uric acid, NGAL = neutrophil gelatinase-associated lipocalin, HOMA-IR = homeostasis model assessment of insulin resistance, LDL = low-density lipoprotein, HDL = high-density lipoprotein, CKD = chronic kidney disease, NAFLD activity score = nonalcoholic fatty liver disease activity score.